Research update of Tolicizumab in the treatment of juvenile idiopathic arthritis
10.3760/cma.j.issn.2095-428X.2015.21.002
- VernacularTitle:托珠单抗治疗幼年特发性关节炎研究进展
- Author:
Xiufen HU
- Publication Type:Journal Article
- Keywords:
Juvenile idiopathic arthritis;
Tocilizumab;
Interleukin - 6;
Interleukin - 6 receptor
- From:
Chinese Journal of Applied Clinical Pediatrics
2015;(21):1604-1607
- CountryChina
- Language:Chinese
-
Abstract:
Tocilizumab is a recombinant humanized monoclonal antibody against interleukin(IL)- 6 receptor (IL - 6R). It can prevent IL - 6 from binding to membrane - bound or soluble IL - 6R,thus blocking IL - 6 mediated signal transduction,and clinically alleviating inflammation and joint destruction in rheumatoid arthritis(RA). Both in the American and European Union,intravenous Tocilizumab has been approved for the treatment of both systemic juve-nile idiopathic arthritis(sJIA)and polyarticular JIA(pJIA)in patients aged ﹥ 2 years old. The approval was based on the favorable results from 2 randomized,double - blind,placebo - controlled,multinational,phase Ⅲ trials conducted in patients aged 2 - 17 years old with active sJIA or pJIA. Tocilizumab was generally well tolerated in patients with sJIA and pJIA. The most frequently reported adverse events in Tocilizumab recipients were infections,neutropenia,impaired liver function,etc.
